Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society - 1 Apr 2012

Gehrig Stefan M, van der Poel Chris, Hoeflich Andreas, Naim Timur, Lynch Gordon S, Metzger Friedrich

Abstract excerpt

OBJECTIVE: Duchenne muscular dystrophy (DMD) is a fatal monogenetic disease with affected males displaying severe and progressive muscle wasting and weakness eventually leading to premature death. Possible therapeutic benefits of insulin-like growth factor I (IGF-I) have been studied extensively in various models of muscle disease and DMD with IGF-I as a mediator of improved skeletal muscle regeneration by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Dystrophin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Insulin-Like Growth Factor I

Share to Mice, Inbred mdx

Share to Muscle, Skeletal

Share to Muscular Dystrophies

Share to Muscular Dystrophy, Duchenne

Share to Polyethylene Glycols

Source

Identifiers

PMID: 22424862
DOI: 10.1016/j.ghir.2012.02.004

Genes

DMD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.PMID 22424862Read ↗

IGF-II ameliorates the dystrophic phenotype and coordinately down-regulates programmed cell death.Semantic proximity Read ↗

Enhanced skeletal muscle fatigue tolerance through cell transplantation-mediated dystrophin supplementation in a mouse model of Duchenne Muscular DystrophySemantic proximity Read ↗

Simvastatin Influences Selected Aspects of Duchenne Muscular Dystrophy Pathology in a Mouse ModelSemantic proximity Read ↗

Skeletal muscle-specific overexpression of IGFBP-2 promotes a slower muscle phenotype in healthy but not dystrophic mdx mice and does not affect the dystrophic pathology.Semantic proximity Read ↗

Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment.Semantic proximity Read ↗

Beneficial effects of insulin-like growth factor-I on wobbler mouse motoneuron disease.Semantic proximity Read ↗

Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery.Semantic proximity Read ↗

Silencing Nfix rescues muscular dystrophy by delaying muscle regenerationSemantic proximity Read ↗

Rescue of dystrophic skeletal muscle by PGC-1α involves restored expression of dystrophin-associated protein complex components and satellite cell signalingSemantic proximity Read ↗

Animal models of muscular dystrophy – what can they teach us?Semantic proximity Read ↗

Interference with Myostatin/ActRIIB Signaling as a Therapeutic Strategy for Duchenne Muscular DystrophySemantic proximity Read ↗

Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.